research Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
The Pfizer COVID-19 vaccine may rarely trigger nail psoriasis.
Search
for
Sort by
Research
210-240 / 1000+ resultsresearch Unraveling the mechanism of action of cepharanthine for the treatment of novel coronavirus pneumonia (COVID-19) from the perspectives of systematic pharmacology
Cepharanthine may help treat COVID-19 by targeting multiple pathways.
research COVID-19 pandemic and teledermatology in low-income regions
The COVID-19 pandemic increased the use of teledermatology to treat skin conditions in low-income areas, despite challenges like poor photo quality.
research A Systematic Scoping Review and Conceptual Analysis of New-Onset Fibromyalgia Manifestations After Non-Hospitalized COVID-19: Empirics, Definitions, Methodologies, Pathophysiology, Mapping of Literature, and Knowledge Gaps
New-onset fibromyalgia after COVID-19 is poorly understood, needing better definitions and studies.
research ВЛИЯНИЕ АНДРОГЕННОГО СТАТУСА И АНТИАНДРОГЕННОЙ ТЕРАПИИ НА ТЕЧЕНИЕ COVID-19 У МУЖЧИН
Men with higher androgen levels may have severe COVID-19 symptoms, but those on antiandrogen therapy are less likely to contract the virus and have milder symptoms. Anti-androgen drugs could potentially treat COVID-19, but more research is needed.
research Hypochlorous Acid: Clinical Insights and Experience in Dermatology, Surgery, Dentistry, Ophthalmology, Rhinology, and Other Specialties
Hypochlorous acid is a safe, effective antimicrobial with potential in various medical fields, but more research is needed to improve its stability and use.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Hormonal trends in patients suffering from long COVID symptoms
Long COVID patients may have hormonal imbalances linked to their symptoms.
research Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review
COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
research Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia
Balancing testosterone may reduce COVID-19 severity.
research Cutaneous manifestations of COVID-19: a case report and review of the literature
Some children with COVID-19 develop skin symptoms linked to a severe inflammatory condition.
research Skin Manifestations in Confirmed COVID 19 Patients; A Short Prospective Multicenter Case Series Cohort Study
COVID-19 can cause different skin issues, including rashes and hair loss.
research Recommendations on trichological treatments during COVID-19 pandemic
Use telemedicine and strict hygiene for safe hair and scalp treatments during COVID-19.
research Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
research PO.8.170 Drug-induced lupus or systemic lupus erythematosus after experimental COVID-19 therapy: difficulties in differential diagnosis
Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.
research Cutaneous Manifestations in COVID-19: Report on 31 Cases from Five Countries
Some COVID-19 patients have different skin problems, which might be the only sign of the virus or related to other health issues.
research Defining the short-term and long-term skin manifestations of COVID-19: insights after more than three years of the pandemic
COVID-19 can cause various skin issues, but long-term skin problems are rare.
research Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
research Clinical symptoms of hyperandrogenic women diagnosed with COVID‐19
Women with high androgen levels may have more severe COVID-19 symptoms.
research A response to “Male balding is a major risk factor for severe COVID-19”
The authors suggest that scalp hair might protect against COVID-19 and call for more research on scalp health and the virus.
research ANDROGENŲ IR ANDROGENINĖS ALOPECIJOS RYŠYS SU COVID-19 INFEKCIJA
Androgens may worsen COVID-19 severity in men.
research Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease
Dupilumab and COVID-19 can worsen or trigger psoriasis.
research Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?
Sex hormones like estrogen and testosterone may affect COVID-19 severity differently in men and women, potentially influencing prevention and treatment strategies.
research Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones
Sex hormones may affect COVID-19 severity, with estrogen possibly reducing risk and testosterone potentially increasing it.
research SYMPTOMATOLOGY AND TREATMENT OF COVID-19 AFFECTING SKIN APPENDAGES: A NARRATIVE REVIEW BEYOND COVID-TOES.
COVID-19 can cause hair loss and nail issues, with treatments available for these conditions.
research Is there a link between androgenetic alopecia and COVID-19?
No clear link between androgenetic alopecia and COVID-19 was found.
research COVID-19感染症でみられる皮膚病変
COVID-19 can cause various skin symptoms, with different patterns seen in younger and older patients.
research Eflúvio telogeno pós-COVID
COVID-19 may cause increased hair loss, but the exact reason is unclear and standard hair loss treatments are recommended.
research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
research Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.